Lexeo Therapeutics, Inc. (LXEO) EBITDA (2022 - 2023)
Lexeo Therapeutics' EBITDA history spans 2 years, with the latest figure at -$15.0 million for Q4 2023.
- For Q4 2023, EBITDA changed N/A year-over-year to -$15.0 million; the TTM value through Dec 2023 reached -$68.5 million, changed N/A, while the annual FY2024 figure was -$98.4 million, 48.26% down from the prior year.
- EBITDA for Q4 2023 was -$15.0 million at Lexeo Therapeutics, up from -$20.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$14.0 million in Q2 2023 and bottomed at -$20.3 million in Q3 2023.